Pharmaceuticals, Biotechnology and Life Sciences
GeNeuro’s results from the Phase 2b study of its novel therapeutic treatment of multiple sclerosis (MS) showed a significant, consistent positive…
Novartis could have the first therapy which could delay disability progression secondary progressive multiple sclerosis (SPMS) if it gets the…
Novartis and Pear Therapeutics will develop new treatments for patients with schizophrenia and multiple sclerosis, with Pear’s prescription digital therapeutics…
Novartis on Tuesday announced positive results from the Phase III PARADIGMS study, investigating the safety and efficacy of oral once-daily…
A person in Germany treated with Roche Holding AG’s new multiple sclerosis drug Ocrevus has been diagnosed with an often-deadly brain infection after switching from another medication earlier this year, the Swiss drugmaker said on Wednesday.
Apitope’s ATX-MS-1467 has reduced the number and volume of brain lesions with a promising safety profile, the company said about results of a test.
GeNeuro and Servierhave set up a study they named ANGEL-MS, which is a long-term extension study for patients with multiple sclerosis…
Sanofi and its subsidiary Genzyme announced positive new five-year investigational data from the extension study of Lemtrada (alemtuzumab) for patients with relapsing remitting multiple sclerosis (RRMS).
Teva Pharmaceutical Industries Ltd. announced on Monday that its glatiramer acetate injection was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW)…